Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Raderer

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
British Journal of Cancer|April 17, 2003
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinomaH Ulrich-Pur, M Raderer, G Verena Kornek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2002
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trialW Scheithauer, B Schüll, H Ulrich-Pur, et al.
The New England Journal of Medicine|October 27, 1994
Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumorsI Virgolini, M Raderer, A Kurtaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III studyW Scheithauer, G Kornek, A Marczell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upE Zucca, L Arcaini, C Buske, et al.
Nuklearmedizin. Nuclear Medicine|November 26, 2014
[Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement]Christina Lindner, J Dierneder, G Pall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapyI Virgolini, P Patri, C Novotny, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|July 31, 2001
New trends in peptide receptor radioligandsI Virgolini, T Traub, C Novotny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
The impact of hemoglobin levels on fatigue and quality of life in cancer patientsB Holzner, G Kemmler, R Greil, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 10, 2004
The role of nuclear medicine in the diagnosis of cancer of unknown originH Demir, F Berk, M Raderer, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
British Journal of Cancer|April 17, 2003
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinomaH Ulrich-Pur, M Raderer, G Verena Kornek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2002
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trialW Scheithauer, B Schüll, H Ulrich-Pur, et al.
The New England Journal of Medicine|October 27, 1994
Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumorsI Virgolini, M Raderer, A Kurtaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III studyW Scheithauer, G Kornek, A Marczell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upE Zucca, L Arcaini, C Buske, et al.
Nuklearmedizin. Nuclear Medicine|November 26, 2014
[Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement]Christina Lindner, J Dierneder, G Pall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapyI Virgolini, P Patri, C Novotny, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|July 31, 2001
New trends in peptide receptor radioligandsI Virgolini, T Traub, C Novotny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
The impact of hemoglobin levels on fatigue and quality of life in cancer patientsB Holzner, G Kemmler, R Greil, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 10, 2004
The role of nuclear medicine in the diagnosis of cancer of unknown originH Demir, F Berk, M Raderer, et al.
Pageof 18